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Multifaceted intervention to enhance cognition in older people at risk of
cognitive decline: Study protocol for the Protein Omega-3 and Vitamin D
Exercise Research (PONDER) study
Abstract
Introduction An increasing number of people are living with cognitive impairment and dementia. Current
pharmacological therapies at best reduce Alzheimer's disease symptomatology but do not delay dementia
onset in those at high risk. Structured exercise interventions can enhance cognition in older people; however,
to produce long lasting, clinically relevant cognitive benefits, it is proposed that a multifaceted approach
incorporating exercise with dietary supplements will address a wider range of mechanisms involved in
cognitive decline. The Protein Omega-3 aNd vitamin D Exercise Research (PONDER) study aims to
investigate the cognitive effects of a multimodal exercise programme combined with nutritional
supplementation in older adults with subjective memory impairment (SMI).
Methods and analysis The PONDER study is a single-centre, 12-month, community-based, parallel group,
randomised, double-blind, placebo controlled trial involving a 6-month multifaceted intervention with a
further 6-month follow-up. Participants will be 148 people from Melbourne, Australia, aged 60-85 years with
SMI who will be randomised (1:1 ratio) to either a 6-month supervised multimodal exercise programme
combined with omega-3 fatty acid, vitamin D and protein supplementation or a stretching/flexibility exercise
programme combined with placebo supplements. The primary outcome is the change in cognition after 6
months as assessed by the Trail Making Test and global cognitive function assessed from the Cogstate
Computerised battery. Secondary outcomes will include memory, working memory/learning and attention/
psychomotor function, the Montreal Cognitive Assessment, mood, quality of life, muscle strength, physical
function, body composition, cardiovascular health and sleep quality. Cognition at 12 months will represent a
secondary outcome.
Ethics and dissemination This study has been approved by the Deakin University Human Research Ethics
Committee (project 2016-260). Informed consent will be obtained from all participants. The authors intend
to submit the findings of the study to peer-reviewed journals or academic conferences to be published.
Trial registration number ACTRN12616001549415; Pre-results.
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AbstrACt
Introduction An increasing number of people are 
living with cognitive impairment and dementia. Current 
pharmacological therapies at best reduce Alzheimer’s 
disease symptomatology but do not delay dementia onset 
in those at high risk. Structured exercise interventions can 
enhance cognition in older people; however, to produce 
long lasting, clinically relevant cognitive benefits, it is 
proposed that a multifaceted approach incorporating 
exercise with dietary supplements will address a wider 
range of mechanisms involved in cognitive decline. 
The Protein Omega-3 aNd vitamin D Exercise Research 
(PONDER) study aims to investigate the cognitive effects 
of a multimodal exercise programme combined with 
nutritional supplementation in older adults with subjective 
memory impairment (SMI).
Methods and analysis The PONDER study is a single-
centre, 12-month, community-based, parallel group, 
randomised, double-blind, placebo controlled trial involving 
a 6-month multifaceted intervention with a further 
6-month follow-up. Participants will be 148 people from 
Melbourne, Australia, aged 60–85 years with SMI who will 
be randomised (1:1 ratio) to either a 6-month supervised 
multimodal exercise programme combined with omega-3 
fatty acid, vitamin D and protein supplementation or a 
stretching/flexibility exercise programme combined with 
placebo supplements. The primary outcome is the change 
in cognition after 6 months as assessed by the Trail Making 
Test and global cognitive function assessed from the 
Cogstate Computerised battery. Secondary outcomes will 
include memory, working memory/learning and attention/
psychomotor function, the Montreal Cognitive Assessment, 
mood, quality of life, muscle strength, physical function, 
body composition, cardiovascular health and sleep 
quality. Cognition at 12 months will represent a secondary 
outcome.
Ethics and dissemination This study has been approved 
by the Deakin University Human Research Ethics 
Committee (project 2016–260). Informed consent will 
be obtained from all participants. The authors intend to 
submit the findings of the study to peer-reviewed journals 
or academic conferences to be published.
trial registration number ACTRN12616001549415; Pre-
results.
IntroduCtIon
Globally, the population is ageing, and the 
number of people living with dementia is 
set to increase by at least 50% in the next 20 
years.1 Delaying dementia onset by as little 
as 6 months could reduce prevalence by 6%, 
with a delay of 5 years predicted to decrease 
prevalence by 44%.2 Therefore, strategies to 
reduce dementia risk factors, delay dementia 
onset and to slow the rate of neuropathology 
are urgently needed to reduce the economic 
and social burden of dementia and related 
cognitive disorders.
Alzheimer’s disease (AD) is a form of 
dementia characterised by progressive neuro-
degeneration, decline in memory and other 
cognitive processes. Current pharmacolog-
ical treatments at best reduce AD symptom-
atology and have not demonstrated efficacy 
to delay dementia onset in those at high risk 
of developing AD.3 Mechanisms contributing 
to the neuropathology of AD are known to 
include neuroinflammation, oxidative stress, 
strengths and limitations of this study
 ► This is the first randomised controlled trial to inves-
tigate the combined effects of a multimodal exercise 
programme with omega-3, vitamin D and protein 
supplementation on cognition in older adults with 
subjective memory impairments.
 ► The exercise programme is structured,  supervised 
and delivered in a community, rather than a labo-
ratory setting.
 ► The study has an additional follow-up period to en-
able assessment of longer term cognitive changes 
(over 12 months).
 ► It was not feasible to examine the isolated effects of 
the exercise programme and dietary supplement in 
separate study arms.
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mitochondrial and cerebrovascular dysfunction.4 Inter-
ventions that target such modifiable processes, while 
promoting neuroplasticity and neuroprotection are 
essential to combat cognitive decline and AD.
Exercise, omega-3 fatty acids and vitamin d for cognitive 
function
Exercise is a candidate to attenuate neuropathology and 
enhance brain health throughout life via the regulation 
of growth factors and neurotrophins such as insulin-like 
growth-factor 1 (IGF-1), brain-derived neurotrophic 
factor (BDNF) and vascular endothelial growth factor 
that are involved in angiogenesis, synaptogenesis and 
neurogenesis and the modulation of systemic inflamma-
tion.5 Exercise can positively influence cardiovascular 
health and insulin resistance, which are pathways relevant 
to cognitive decline.6 A large body of research has demon-
strated that greater levels of physical activity are associ-
ated with slower rates of cognitive decline7 and a lower 
risk of dementia.8 Furthermore, randomised controlled 
trials (RCTs) have shown that even acute bouts of exercise 
can provide small benefits to cognition.9 Findings from 
recent meta-analyses have indicated that longer duration 
exercise interventions can enhance cognition in healthy 
p eople>50 years of age10 as well as individuals at risk of or 
diagnosed with AD.11
While questions still remain regarding the optimal 
mode and dose of exercise required for cognitive improve-
ments,12 a recent systematic review and meta-analysis of 
36 RCTs in community-dwelling adults, aged 50 years and 
above,10 provided the recommendation that combined 
aerobic and resistance exercise, at a moderate to high 
intensity, as many days of the week as feasible, is suitable 
to enhance cognitive function. Exercise interventions of 
4–6 months’ duration that have used resistance or multi-
modal programmes, incorporating resistance training, 
have indicated that, in older people, a frequency of 
two sessions per week can benefit cognition.13–15 Impor-
tantly, cognitive benefits have been observed for resis-
tance training when compared with ‘sham’ exercise or 
stretching conditions designed not to impact heart rate 
or aerobic capacity.13 14 16 The use of a control exercise 
condition that is matched for social interaction, including 
attention from the trainer delivering the programme, is 
necessary to account for possible benefits to cognition 
attributed to the social experience, rather than the exer-
cise programme.
Accumulating evidence, largely from epidemiological 
studies, suggests that various dietary factors alone and 
in combination, particularly omega-3 fatty acids and 
vitamin D, are strongly linked with cognitive decline 
and dementia.17–20 Polyunsaturated fatty acids (PUFAs) 
serve an essential role in the brain, regulating the func-
tion and structure of neurons, endothelial cells and glial 
cells.21 The long-chain omega-3 fatty acids eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA) also 
modify neurotransmission, reduce neuroinflammation 
and promote neuronal survival and neurogenesis.21 The 
high intake of omega-6 fatty acids in the Western diet 
(ie, from vegetable oil) causes an imbalance of omega-
3/6 fatty acids, resulting in lower than optimal levels of 
DHA and EPA.22 23 A high intake of omega-6 fatty acids 
has been suggested to adversely impact cognition by 
depleting DHA, the omega-3 PUFA most prevalent in 
the brain.24 In contrast, a low omega- 6/3 ratio has been 
shown to predict better cognitive function in healthy 
older people.25
Greater dietary intake of DHA (from consumption of 
fish) has been linked to better cognitive outcomes in older 
people26 and a 36% lower risk of AD across multiple obser-
vational studies.17 A dose–response meta-analysis showed 
that an increment of 100 g per week of fish intake was 
associated with an 11% lower risk of AD.17 In older people 
with mild memory complaints (n=437) 900 mg/day of 
DHA supplementation for 24 weeks improved episodic 
memory and learning on computerised measures.27 Of 
note, when compared with normative data, the improve-
ments due to DHA supplementation on the verbal learning 
test approximated a 7-year improvement, compared with 
a 3.6-year improvement with placebo. Another study 
conducted in 50 older people with mild cognitive impair-
ment found that both EPA rich (1.67 g EPA+0.16 g DHA/
day) and DHA rich (1.55 g DHA+0.40 g EPA/day) supple-
ments, taken daily for 6 months, improved depressive 
symptoms, compared with an omega-6 rich supplement.28 
In this study, only the DHA-rich supplement improved a 
single cognitive domain as well as physical health. As not 
all studies have yielded positive results regarding omega-3 
fatty acid supplementation on cognitive function,29–31 
dose and target population may be crucial factors.
An emerging role for vitamin D in the maintenance of 
brain health and cognition is developing with reports that 
serum 25-hydroxyvitamin D (25(OH)D) levels are lower 
in those with impaired cognitive function and AD than 
healthy controls18 32 and low vitamin D levels increase AD 
risk 7 years later.33 Observational studies indicate that 
inadequate vitamin D intake is linked to poorer cognitive 
function34 and may increase the probability of cognitive 
impairment by as much as 30%.35 Relatively few RCTs 
have investigated the impact of vitamin D supplementa-
tion on cognition in older adults,35 although clinical trial 
registries indicate a number of studies are underway. In 
a recent 18-week study comparing high-dose vitamin D3 
(4000 IU/day) to a low dose (400 IU/day) in 82 healthy 
adults, the high-dose supplementation improved visu-
ospatial memory but not other cognitive domains.36 As 
even the low dose increased 25(OH)D concentrations 
above 75 nmol/L, this may have impacted the ability to 
detect cognitive changes dues to higher dose supplemen-
tation, as 75 nmol/L  is the suggested optimum value to 
exceed to reduce cognitive and brain dysfunction.37
Whether there is an additive effect of different nutri-
ents with exercise in terms of benefits to brain health 
is an important question. Research in rodents has indi-
cated that DHA can enhance the effects of exercise on 
BDNF-related synaptic plasticity,38 and vitamin D has 
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the potential to contribute to these actions through the 
regulation of neurotrophins BDNF, glial cell line-derived 
neurotrophic factor, nerve growth factor and IGF-1.35 As 
a neuroprotective agent, vitamin D may target specific 
AD pathology, attenuating amyloid-beta (Aβ) accumula-
tion by stimulating the phagocytosis of the Aβ peptide 
and inducing cytokines and macrophages to increase Aβ 
clearance.35 Exercise and DHA exert potent anti-inflam-
matory effects5 21 and vitamin D may further attenuate 
inflammation-induced degeneration of neurons by inhib-
iting the production of tumour necrosis factor-α, inter-
leukin-6 and nitric oxide, preventing lipid peroxidation 
and reversing mitochondrial dysfunction under condi-
tions of heightened oxidative stress.35
The cognitive effects of omega-3 fatty acids combined 
with a more complex lifestyle intervention, incorporating 
exercise, have recently been examined in the large 3-year 
RCT Multidomain Alzheimer Prevention Trial (MAPT). 
This study examined the impact of omega-3 fatty acid 
supplementation (800 mg/day DHA +250 mg/day EPA) 
and a multidomain intervention (cognitive training, 
physical activity and nutrition advice and three preven-
tative consultations), alone or in combination, compared 
with placebo on cognitive function in 1680 communi-
ty-dwelling, non-demented adults aged 70+ years.39 The 
combination of omega-3 fatty acids and the multidomain 
intervention enhanced cognitive performance on a 
secondary measure of cognitive function and in subgroup 
analyses of those with an increased dementia risk score, 
but no benefits were found for the primary cognitive 
endpoints. The absence of an effect on the primary 
outcome for the multidomain intervention may have 
been influenced by the design of the exercise component 
that was limited to generic physical activity advice to be 
more active (eg, aim to walk 30 min per day) and did not 
include a structured programme designed to enhance 
physical function.
Muscle mass and strength and cognitive function
The ageing process targets multiple systems of the 
body, leaving older individuals vulnerable to deteriora-
tion of brain, vascular and musculoskeletal systems. A 
progressive loss of muscle mass, strength and function, 
termed as sarcopenia, occurs with ageing. After the age 
of 40–50 years, there is a progressive loss of muscle mass 
in the magnitude of 1%–2% per year.40 Sarcopenia is a 
growing public health concern, increasing the risk of 
low trauma fracture, disability, morbidity and reducing 
quality of life in older people.40
Low muscle strength has been linked to lower global 
cognitive performance41 and a higher risk of cogni-
tive impairment.42 Greater frailty has been associated 
with increased cognitive decline in patients with AD.43 
A recent investigation using data derived from the UK 
Biobank identified a significant relationship between grip 
strength and multiple cognitive domains in over 475 000 
individuals from the general population.44 While these 
findings emphasise the connection between muscular 
strength and brain health, more research is needed to 
determine whether increasing muscle mass and strength 
can enhance cognitive function. Results from the Study 
of Mental and Resistance Training (SMART) trial showed 
that strength improvements due to 6 months of high 
intensity resistance training were associated with improve-
ments to cognitive function in older people with mild 
cognitive impairment.45
Combining dietary protein supplementation with resis-
tance training exercise has been proposed as a strategy 
to offset muscle decline in older people.46 A 16-week 
RCT conducted in older women found that increasing 
lean red meat intake, combined with twice weekly resis-
tance training, increased lean tissue mass and muscle 
strength compared with resistance training coupled with 
a high carbohydrate diet.47 A recent meta-analysis has 
confirmed that dietary protein can augment the effects of 
resistance training exercise on muscle mass and strength, 
although the findings indicate that resistance training is 
the more potent stimulus for increasing muscle strength 
than protein intake.48 Protein dose may be an important 
consideration, with an RCT in men aged >70 years having 
demonstrated that providing double the recommended 
daily allowance (RDA) of protein (1.6 g protein/kg/day), 
compared with the RDA, for 10 weeks provided bene-
fits to lean body mass and knee extension peak power.49 
These findings are consistent with the premise that 
older adults need a higher intake of protein to increase 
muscle protein synthesis.46 With regards to the impact of 
combining exercise with protein on cognitive function, 
there is some evidence that the combination of 30 g daily 
protein supplementation and resistance training exer-
cise for 6 months enhanced processing speed in frail and 
prefrail elderly.50 While a consistent benefit of protein 
supplementation for cognition has not been established, 
it has been proposed that amino acids such as tyrosine 
and tryptophan may be capable of modulating cognitive 
function.51
objective
It is hypothesised that a multifaceted approach combining 
exercise with dietary modification involving omega-3 fatty 
acids, vitamin D and protein may offer cognitive bene-
fits, relative to the control condition, as they will target 
complementary pathways related to neuroinflammation, 
neuroprotection and neuroplasticity.5 21 35
The primary aim of this study is to investigate the efficacy 
of a 6-month multifaceted intervention, incorporating an 
exercise programme with omega-3 fatty acid, vitamin D 
and protein supplementation on cognitive function in 
older people with subjective memory complaints. The 
secondary aims are to: (1) determine if any beneficial 
effects of this intervention on cognitive function are medi-
ated through increases in muscle strength or mass, (2) 
explore the impact of the intervention on other aspects 
of psychological and physical health and (3) evaluate the 
longer term residual effects (6 months after cessation of 
the intervention) on cognition.
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This is a 12-month, community-based, parallel group, 
randomised, double-blind, placebo-controlled trial 
involving a 6-month supervised and structured inter-
vention, followed by an additional 6-month follow-up 
to evaluate any long-term residual effects. A total of 148 
individuals with subjective memory impairment (SMI) 
aged 60–85 years will be randomised to: (1) a supervised 
multimodal exercise programme involving progressive 
resistance training and aerobic exercise, combined with 
omega-3 fatty acid, vitamin D and protein supplementa-
tion or (2) a stretching/flexibility exercise programme 
and placebo supplements. During the 6-month postinter-
vention follow-up, participants will no longer be provided 
with the exercise programmes or supplements but will be 
encouraged to continue to exercise and follow a healthy 
diet. This study protocol is reported in accordance with 
the Standard Protocol Items: Recommendations for Inter-
ventional Trials statement,52 and results will be reported 
in line with the Consolidated Standards of Reporting 
Trials (CONSORT) statement53 and the CONSORT 
statement for non-pharmacological interventions.54 The 
study was prospectively registered on the Australian New 
Zealand Clinical Trials Registry on 10 November  2016.
Participants and screening
Participants will be included into the study based on the 
following criteria: (1) presence of subjective memory 
complaints, defined as a positive response to the ques-
tion ‘do you feel like your memory is becoming worse?’ 
and a score >17 on the Montreal Cognitive Assessment 
(MoCA), (2) community dwelling and aged 60–85 years, 
(3) fluent in written and spoken English and (4) with 
normal or corrected to normal vision and hearing.
To minimise extraneous causes of cognitive impair-
ment, participants will be excluded based on the 
following: (1) diagnosis of AD or other dementia and 
Parkinson’s disease; (2) history of brain damage including 
significant head trauma, stroke or serious neurological 
disorder, including loss of consciousness >24 hours; (3) 
clinical diagnosis of psychiatric disorder likely to affect 
cognition, including current clinical diagnosis of depres-
sion, commencement of anti-anxiety or antidepressant 
medication within the past 6 months, score of >5 on the 
short Geriatric Depression Scale; (4) or alcohol or drug 
dependency within the last 2 years. Exclusion criteria 
relevant to the study intervention, supplement and/or 
exercise programme, will include: (5) existing diagnosed 
gastrointestinal disorders likely to impact absorption of 
fatty acids (eg, coeliac disease); (6) known allergy to fish 
or any other component in the dietary supplement; (7) 
type two diabetes; (8) body mass index >40; (9) health 
conditions that contraindicate exercise or insufficient 
mobility to exercise; (10) participating in progressive 
resistance training >1 week or more >150 min per week 
of moderate intensity physical activity; (11) current 
smokers; (12) oily fish consumption (≥1/week); (13) 
daily use of omega-3 rich supplement >500 mg or vitamin 
D supplements >500 IU within the past 12 weeks; (14) use 
of cholinesterase inhibitors, benzodiazepines, antipsy-
chotics or high-dose antidepressants (judged by medical 
advisor), use of warfarin or high dose blood thinners, 
resistant hypertension defined as the use of more than 
three antihypertensive agents and medications contra-
indicated for use with omega-3 fatty acids, vitamin D or 
protein. Any uncertainty or discrepancies about partici-
pants’ clinical history will be resolved by consulting with a 
physician familiar with the study (investigator SM).
Participants will be recruited from within the local 
community in Melbourne (Australia) and surrounding 
areas via newspaper advertisements, community presenta-
tions, social media and community notice boards. Partic-
ipants will be provided with the exercise programme free 
of charge as an incentive to participate in the trial.
randomisation
Participants will be randomly allocated to one of the two 
parallel groups using a simple randomisation computer 
generated random sampling set, with an allocation ratio 
of 1:1. Randomisation will be stratified for gender and age, 
separated into three categories of 60–69.9 years, 70–79.9 
and 80–85.9 years. Randomisation will be conducted by 
personnel not otherwise involved in the trial. Participant 
group allocation will be provided in an opaque envelope 
to the researcher involved in assigning participants to the 
intervention, on completion of the baseline appointment. 
The researcher who assigns participants to the interven-
tion will distribute the study treatment and provide infor-
mation about the assigned exercise programme. This 
researcher will no longer be blinded from this point.
blinding
Both the active supplement and the placebo will be pack-
aged in non-transparent sachets. All researchers involved 
in outcome assessments will be blinded to participant 
group allocation, with the exception of the 6-month 
dual-energy X-ray absorptiometry (DXA) scan, which 
may be conducted by an unblinded researcher due to 
limited qualified personnel. All DXA analyses will be 
carried out by a blinded researcher. During the interven-
tion period, only unblinded researchers will be in contact 
with participants enrolled in the trial. In order to main-
tain a double-blind study design, participants will not be 
informed that all individuals assigned to the multimodal 
exercise programme will also receive the supplement 
drink containing omega-3, vitamin D and protein, nor 
that all participants assigned to the stretching/flexibility 
condition will also receive the placebo. The purpose of 
concealment will be explained when all participants have 
completed the trial. Exercise trainers delivering the exer-
cise programme will not be informed that participants in 
the multimodal exercise programme are receiving the 
active supplements or those in the stretching group are 
receiving the placebo. All data analysis will be completed 
by personnel who are blinded to the intervention 
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assignment. Participants will be unblinded after the 
12-month assessment.
The codes will only be broken in an emergency, such 
as a severe adverse event that requires knowledge of 
the treatment being taken in order to manage a partic-
ipant’s condition. The principal investigator and ethics 
committee will be informed within 24 hours of the code-
break envelope being opened.
Intervention
Multimodal exercise programme plus omega-3, vitamin D and 
protein supplement drink
Exercise intervention: participants will take part in a 
6-month group community-based programme designed 
by an exercise physiologist, conducted within local health 
and fitness centres located in Melbourne, Australia. 
Participants will attend 2×1 hour weekly supervised exer-
cise sessions for 6 months at a health and fitness centre 
in close proximity to their home. Exercise classes will 
be exclusive to PONDER study participants and will not 
exceed 10 participants. Exercise sessions will be supervised 
by a dedicated, accredited exercise trainer. Each exercise 
session will involve a 5–10 min group warm up, 15 min of 
aerobic exercise followed by approximately 30–40 min of 
progressive resistance training concluding with a 5 min 
cool down. The aerobic exercises will be rotated rather 
than progressed. In line with current recommendations 
to enhance cognition,5 the progressive resistance training 
will consist of two sets of 8–12 repetitions, at a weight that 
cannot be lifted for more than these number of repeti-
tions, at a rating of perceived exertion of 5–8 (‘hard to 
very-hard’) on the 10-point scale.55 This will be completed 
for eight resistance exercises involving dynamic concen-
tric and eccentric contractions targeting all the major 
muscle groups and with an emphasis on weekly progres-
sive overload (increments of 2%–10%). Details of the 
multimodal programme are shown in table 1.
Supplement: the study treatment will be a vanil-
la-flavoured daily supplement drink containing 5 g of 
omega-3 powder (18% EPA, 12% DHA equivalent to 
900 mg EPA and 600 mg DHA), vitamin D3 1000 IU and 
25 g of whey protein concentrate (WPC) 80. The total 
of 1.5 g omega-3 fatty acids is a physiologically relevant 
dose (equal to half portion of farmed Atlantic salmon or 
a full portion of fresh or tinned wild Atlantic salmon).56 
The aim of 1000 IU/day vitamin D3 treatment is to raise 
serum 25(OH)D concentrations to at least 50–60 nmol/L, 
in line with current Australian recommendations.57 When 
combined with resistance training, 20 g of whey protein 
isolate has been demonstrated to increase muscle protein 
synthesis in older people58; therefore, 25 g of WPC was 
selected to provide a comparable dose of protein. Each 
drink will provide approximately 590 kJ of energy, 2 g 
of lactose, 6 g of fat and 20 g of protein. The supple-
ment will be provided in powder form to be mixed with 
200 mL water. The treatments have been developed by 
Omniblend Australia. Participants will be instructed to 
Table 1 Details of the exercise programmes
Multimodal exercise 
Frequency 2× per week. 
Intensity RPE rating of 5–8 (hard to very hard). 
Duration 60min. 
Warm up 5min group-based warm up including balance and mobility exercises. 
Aerobic 15 min aerobic training rotating exercises: treadmill, bike, stepper, rower, X-trainer/elliptical trainer and so on. 
Resistance  30–40 min resistance training: eight exercises (six resistance, two core), two sets, 8–12 reps targeting all 
the major muscle groups and with an emphasis on weekly progressive overload (increments of 2%–10 %). 
Resistance exercises may include: squats / leg press, lat pulldown, calf raises, chest press/seated row, 
modified plank and so on. 
Cool down 5–10min cool down: relaxation type exercises incorporating stretching. 
Stretching and flexibility. 
Frequency 2× per week. 
Intensity Light
Duration 50–60 min. 
Warm up 5 min light walking/marching, range of motion exercises. 
Aerobic Nil.
Resistance Nil.
Flexibility 35–40 min variety of light stretching/flexibility exercise and light resistance band exercises that will not 
increase strength. 
Cool down 5–10 min cool down: relaxation type exercises. 
RPE, rating of perceived exertion.
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consume the supplement immediately before breakfast, 
except on days involving the exercise programme, when 
they will be requested to consume the supplement 1–2 
hours after completing the session. To reduce the likeli-
hood of any gastrointestinal side effects, participants will 
be instructed to consume only half the supplement dose 
for the first 7 days of the intervention.
Control group (stretching/flexibility programme+placebo drink)
Exercise: participants will complete a 6-month group 
community-based stretching/flexibility programme 
designed by an exercise physiologist within local health 
and fitness centres. Participants will attend 2×1 hour 
weekly supervised exercise sessions for 6 months. Groups 
will be exclusive to study participants. The exercise 
programme will involve stretching and is designed not 
to influence heart rate, strength or aerobic capacity but 
to provide a similar level of social contact and attention 
from a dedicated exercise trainer at each centre. Details 
of the stretching/flexibility programme are shown in 
table 1.
Supplement: the placebo drink will be vanilla flavoured 
and matched for appearance and caloric content and will 
contain 16 g whole milk powder and 15 g maltodextrin. 
Each drink will provide approximately 590 kJ of energy.
Compliance
Compliance to the exercise programmes will be assessed 
using attendance records and for the multimodal 
group, monthly exercise cards collected from the exer-
cise trainers. Each exercise card contains information 
regarding sessions attended, exercises completed, set, 
repetitions, time and training intensity. A compliance 
calendar showing each month will be provided to assess 
supplement compliance. Participants will mark off each 
day the supplement is consumed and record any reasons 
for variations (ie, missed supplement or taken later in 
the day). Participants who are non-compliant with the 
intervention will still be requested to attend all follow-up 
appointments.
Adverse events
Any adverse events potentially or confirmed to be asso-
ciated, with the exercise programme will be recorded 
on the exercise cards provided to the exercise trainers. 
The supplement calendar will be used to record adverse 
events potentially due to the supplement. Any health-re-
lated unfavourable or unintended medical occurrence 
(eg, sign, symptom, syndrome and illness), deemed to be 
relevant to the study, that develops or worsens during the 
trial will be classed as an adverse event. All adverse events 
will be assessed for seriousness, severity, causality and 
expected outcome by the researchers. There will be no 
formal data monitoring committee, due to the size of the 
study and the single site; however, all data will be reviewed 
by the research team at regular intervals throughout the 
study.
sample size calculation
To date, no studies have investigated the cognitive effects 
of the specific intervention combination examined in 
the current study. For this reason, the anticipated effect 
size is largely based on findings derived from the exer-
cise literature. Exercise exerts an average 0.5 SD effect 
size (equating to a medium effect size) on executive 
function.5 A recent meta-analysis has indicated that multi-
modal exercise interventions of at least 4 weeks’ duration 
have a positive effect on cognition in the order of a 0.33 
effect size, in people over the age of 50 years.10 Based on 
these figures, we anticipate at least a medium effect size 
(f=0.25). Allowing for 15% attrition rate, a sample of 148 
participants, with 74 individuals assigned to each study 
arm, will provide a power level of 0.8 at the 5% proba-
bility level.
Procedure
Participants will attend a total of four visits to Deakin 
University in Melbourne to undergo study assessments 
(see figure 1). All participants will be requested to abstain 
from alcohol for 24 hours prior to study visits. No caffeine 
is to be consumed 2 hours prior to study visits, and partic-
ipants will consume the same food and drink at the base-
line (V1) and 6-month (V2) visits. Baseline and 6-month 
visits will be held at the approximate same time of day 
(within 2 hours).
 ► Prescreening: all participants will undergo telephone 
screening.
 ► Screening (V0): potential participants who meet the 
prescreening study criteria will attend a face-to-face 
session with a researcher to provide written informed 
Figure 1 Flow diagram: participant recruitment and 
screening flow chart.
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consent and undergo screening for inclusion/exclu-
sion criteria. Eligible individuals will undergo famil-
iarisation of core study measures and will be provided 
with a physical activity monitor and pathology collec-
tion requests to complete blood collection prior to 
V1. Participants requiring medical approval must 
obtain this prior to baseline.
 ► Baseline (V1): to be conducted within 4 weeks of the V0 
screening visit. During V1, cognitive assessments will 
be carried out first, followed by cardiovascular meas-
ures, anthropometry, DXA, functional measures and 
questionnaires. On completion of V1, participants 
will be allocated to either the intervention group or 
control group and provided with the supplement and 
details of the relevant gym programme. Participants 
are requested not to commence additional omega-3 
or vitamin supplementation during the trial or to take 
part in more than one additional structured exercise 
class per week.
 ► Intervention period: an unblinded study member will 
remain in contact with participants via telephone and 
face-to-face visits at the gyms and will collect exercise 
cards, including adverse event logs and supplement 
compliance logs. Possible adverse events, gym non-at-
tendance and supplement non-compliance will be 
followed up by telephone by an unblinded researcher.
 ► 6 month follow-up (V2): participants will repeat physical 
activity monitoring and blood collection within the 
week prior to V2. All measures from baseline will be 
repeated along with the MaCA.
 ► 12-month follow-up (V3): due to funding constraints, 
only cognitive assessments including the Cogstate, 
Trail Making Test and MoCA and study questionnaires 
will be completed at V3.
Primary outcome
Change in global cognitive function derived from the 
CogState computerised battery and the Trail Making Test 
after 6 months.
secondary outcomes
Changes in cognitive function for the six individual 
measures and the composite scores of working memory/
learning and attention/psychomotor function assessed 
using the CogState battery, the Trail Making Test, the 
MoCA after 6 months and 12 months, and changes in 
mood, health-related quality of life, strength, physical 
function, body composition, cardiovascular health and 
sleep quality after 6 months. A list of outcomes and time 
points are shown in table 2.
screening measures
The self-administered 15-item Short Form Geriatric 
Depression Scale (GDS)59 will be used to screen for the 
presence of depression at V0. Scores greater than 5 poten-
tially indicate depression and those who score >5 will not 
be eligible for the study. The interviewer administered 
MoCA60 will be used to screen for the possible presence 
of dementia. The MoCA is scored out of 30 and assesses 
short-term memory, visuospatial ability, executive func-
tion, verbal fluency, attention and working memory and 
orientation to time and place and is summed to create 
a global measure of cognition. Participants require 
a score >17 to be eligible for the study. The MoCA has 
been shown to have 90% sensitivity and 87% specificity 
for detecting MCI (n=94) and 100% and 87%, respec-
tively, for detecting early AD.60 The MOCA will be used 
for screening purposes at V0 and repeated as a secondary 
outcome after 6 months (V2) and 12 months (V3).
Primary outcome measures
Cognitive assessments
The Cogstate Computerised Battery ( www. cogstate. 
com) will be used to assess cognition for six cognitive 
tasks, which will form the basis for two composite scores 
(working memory/learning and attention/psychomotor 
function) and a measure of global cognitive function, 
which will be the primary outcome. The individual 
cognitive tasks include the Detection Task (reaction time 
task measuring psychomotor function), the Identification 
Task (choice reaction time task measuring visual atten-
tion), the One Card Learning Task (visual recognition 
memory and attention) and the One-Back Task (working 
memory and attention). For all tasks, speed (reaction 
time in milliseconds) and accuracy (number of correct 
responses made) will be recorded. The fifth task is the 
Groton Maze Task, which assesses executive function and 
is calculated based on the number of errors. The final 
task is the International Shopping List (verbal learning and 
memory), which is scored using accuracy, calculated by 
summing correct responses. Individual raw scores for 
each task will be transformed into a z-score using the 
mean and SD of the total sample in the study. Composite 
scores for working memory/learning will be calculated by 
averaging the standardised scores (z-score) for the One 
Card Learning and One-Back Tasks, and the attention/
psychomotor function composite will be calculated by 
averaging the z-scores for the Detection and Identifica-
tion Tasks. Global cognitive function will be derived as 
the average z-scores from all six tests, which higher scores 
indicating better performance. The CogState computer-
ised tasks are specifically designed for repeated adminis-
tration over short time periods and have been validated 
in older adults.61–63 Practice or fatigue effects are minimal 
for these tasks, making them suitable for detecting subtle 
cognitive changes.61–63 To further minimise practice 
effects, the entire battery will be practised at V0.
The Trail Making Test64 65 Part A (visuoperceptual 
ability) involves drawing lines to connect numbered 
dots in ascending numerical order as quickly as possible 
while still maintaining accuracy. Part B (working memory 
and task-switching ability) involves connecting dots in 
ascending order, alternating between numbers and letters 
as quickly as possible. The score is the number of seconds 
taken to complete each part of the test. The score from 
Part B minus Part A provides an indication of executive 
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function65 and will be considered the primary outcome 
generated from the Trail Making test. The Trail Making 
Test has test–retest reliability ranging from 0.74 to 0.85.66 
To minimise practise effects, the Trail Making Test will be 
practised at V0.
secondary outcome measures
Mood, quality of life and sleep
The 21-item Depression, Anxiety and Stress Scale 
(DASS)67 will be used to assess mood. The DASS consists 
of three subfactors that yield subscores for each domain: 
depression, anxiety and stress. Higher total scores indi-
cate a higher degree of mood dysfunction.
The self-administered Short Form 36 version 2 (SF-36 
v2) questionnaire will be used to measure health-related 
quality of life.68 The SF-36 covers the domains of physical 
functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional and mental 
health. The current study will report Australian norm-
based scores using previously published guidelines69 to 
provide each domain score a standardised mean of 50 
Table 2 Outcome measures and relevant data collection time points










  Cognitive function Cogstate Computerised Battery Practice X X X
Trail Making Test Practice X X X
Additional outcomes
Cognitive function
Montreal Cognitive Assessment X X X
NART-R IQ X
Cognitive Function Instrument X X X
  Muscle strength 3RM Knee extension Practice X X
Hand grip strength X X
  Physical function Four Metre Walk Test X X
Four-Square Step Test X X
30 s Sit-to-Stand Test X X
Timed Up and Go Test X X
  Mood Short Geriatric Depression Scale X
Depression Anxiety Stress Scale X X X
  Quality of life Short-form (SF)-36 version 2 X X X
  Sleep Pittsburg Sleep Quality Index X X X
  Personality Short NEO-Personality Inventory X
  Demographics/lifestyle Lifestyle Questionnaire X X X
  Anthropometry Body mass index X X
Hip, waist and neck circumference X X
  Body composition DXA (total body and regional) X X
  Cardiovascular function Resting blood pressure
  Central arterial pressure, pulse wave velocity and 
arterial stiffness
X X
  Diet ASA-24 Dietary Assessment Tool X X X
PUFA Questionnaire X X
  Habitual 
physical activity
CHAMPS Survey X X X
7-day physical activity (Actigraph) X X X
  Biomarkers Cholesterol and HsCRP X X
Omega-3 fatty acids and vitamin D X X
Apolipoprotein E e4 status X
3RM, three repetition maximum; ASA-24, Automated Self-Administered 24 hours; CHAMPS, Community Healthy Activities Model Program for 
Seniors; DXA, dual-energy X-ray absorptiometry; HsCRP, high-sensitity C reactive protein; NART-R IQ, National Adult Reading Test Revised 
IQ; PUFA, polyunsaturated fatty acids. 
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and a SD of 10. Separate quality of life summary scores 
will be calculated for the physical component and the 
mental component.
The self-administered 19-item Pittsburgh Sleep Quality 
Index (PSQI) will be used to measure sleep quality and 
disturbance over a 4-week period.70 The scale is composed 
of items that generate seven subscores: subjective sleep 
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbance, use of sleep medications and 
daytime dysfunction. Both the total score and subscores 
will be outcomes for this measure.
Muscle strength
Lower body muscle strength will be determined by the 
Keiser bilateral knee extension machine (Keiser Corpo-
ration, Fresno, California, USA), using a standard 
three repetition maximum protocol (see ref 71). Partic-
ipants will warm up with 8 repetitions at 3 kg. The weight 
will be increased progressively to participant’s estimated 
three repetition maximum (kg). After a 2 min rest, resis-
tance will be increased (or decreased) until only three 
repetitions in good form can be completed.
Bilateral maximal isometric grip strength will be 
measured using a hand-held dynamometer (Jamar dyna-
mometer, Asimov Engineering Co, Los Angeles, Cali-
fornia, USA). In a seated position, with elbow flexed at 
90°, forearm neutral and hand slightly extended, partici-
pants will be instructed to squeeze the hand grip as tightly 
as possible and release for three trials with a 1 min rest 
between trials. After a practise trial, the maximal grip 
strength (kg) of each hand will be recorded. The test 
is performed by both the dominant and non-dominant 
limbs.
Physical function
All functional tests will be preceded by a practise trial. 
The 4 m walk test will be used to assess gait speed. Partici-
pants walk in a straight line at their normal walking speed 
across four metres with speed recorded using timing gates 
(Swift Speedlink Performance Equipment systems). The 
outcome will be the fastest time measured in seconds (to 
the nearest millisecond) from two trials. 
The Four-Square Step Test (FSST) will be used to assess 
dynamic standing balance and stepping speed in four 
different directions.72 The FSST is completed first in a 
clockwise and then counter-clockwise direction. Partici-
pants will complete two test trials, and the outcome will 
be the fastest time (in seconds) taken to complete the 
sequence.
The Timed Up and Go Test measures dynamic balance 
during three commonly performed functional activities: 
standing up from and sitting down in a chair, walking and 
turning.73 Participants are required to stand up from a 
chair, walk as quickly as possible around a cone (marking 
3 m), turn and walk back to the chair and sit down. The 
outcome will be the time (in seconds) to complete the 
sequence.
The 30 s Sit-to-Stand Test74 will be used to assess lower 
extremity muscle strength and power. Starting from a 
seated position in a chair, chair measuring 45 cm from the 
ground, with arms folded across the chest, participants 
stand fully upright and then return to the seated posi-
tion as many times as possible in 30 s. The outcome is the 
number of sit-to-stands completed in 30 s.
Anthropometrics and body composition
Height will be measured in centimetres using a stadi-
ometer fixed to the wall, and weight will be measured in 
kilograms using calibrated scales with standardised proto-
cols. Body mass index (BMI) will be calculated as weight 
(kg)/height (m2). Waist and hip circumference will be 
measured in centimetres using the WHO protocol.75 
Waist-to-hip ratio will be calculated by dividing the waist 
circumference measurement by the hip circumfer-
ence. Neck circumference will be measured around the 
midpoint of the participant’s neck, between the midcer-
vical spine and mid anterior neck. All measures will be 
taken twice and the average value used as the outcome.
Dual-energy X-ray Absorptiometry (DXA) will be used 
to assess body composition (fat, lean and bone) (Lunar 
iDXA, version Encore 16.2, GE Healthcare Medicine, 
Wisconsin, USA). Total body lean mass, fat mass and 
percentage body fat will be determined from the total a 
regional (arm and legs) body. Standardised procedures 
(2015 ISCD official positions) for participant positioning 
and scan analysis will be used for all scans (https://www. 
iscd. org/ official- positions/ 2015- iscd- official- positions- 
adult/). During each visit participants will be scanned 
in a hospital gown and instructed to remove all metal 
objects. All scans for all participants will be performed by 
the same operator on the same scanner following daily 
quality assurance and control monitoring.
Cardiovascular health
Seated blood pressure will be assessed using an ambu-
latory blood pressure monitor. The blood pressure cuff 
will be fixed to the left arm following a 5 min period of 
seated rest. Four consecutive measurements will be taken 
at 1 min intervals and the average of the final three read-
ings will be used as the outcome.
The SphygmoCor XCEL (AtCor Medical PTY) will 
be used to measure central arterial pressure waveform, 
pulse wave velocity (PWV) and arterial stiffness. Pulse 
wave analysis (PWA) will be measured after 5 min of quiet 
supine rest with the cuff attached to the left arm held in 
a straight position. Measures will be taken twice and the 
average value used at the outcome. To conduct carot-
id-femoral PWV, a cuff will be placed around the femoral 
artery to capture the femoral waveform, and a tonometer 
will capture the carotid waveform. The distance between 
the carotid and femoral arteries will be measured, and the 
velocity automatically calculated by dividing the distance 
by the pulse transit time. Measures will be taken twice, 
with a third measure completed if the difference between 
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the PWV readings is >0.5 m/s. The average value will be 
used at the outcome.
demographic variables and potential covariates
Demographic and lifestyle information will be collected 
on participant’s ethnic and educational background, 
employment history/status, medical history, history of 
falls and fractures, family history of osteoporosis, current 
medication and dietary supplement use, alcohol intake, 
weekly television viewing and sitting time and sun expo-
sure habits.
Cognitive and psychological factors
The National Adult Reading Test-Revised (NART-R) 
will be used to estimate IQ.76 The NART-R is suitable to 
assess premorbid intellectual functioning in the pres-
ence of cognitive impairment.77 The number of errors in 
pronunciation will be converted to an estimate of Full-
Scale IQ score. The Cognitive Function Instrument78 is a 
self-report measure of 14 items that probe experiences of 
memory decline over the past year. This measure will be 
used to provide greater detail regarding subjective cogni-
tive complaints and has been demonstrated to correlate 
with objective cognitive decline.79 The short 60-item NEO 
Personality Inventory will be used to assess the five major 
personality domains of extraversion, agreeableness, 
conscientiousness, neuroticism and openness to expe-
rience80 as personality characteristics may contribute to 
subjective cognitive complaints.81
Blood biomarkers
Within 7 days prior to baseline (V1) and 6 months (V2), 
participants will attend a commercial pathology clinic 
collection centre where a fasted, morning (08:00–10:00) 
venous blood sample will be collected. Blood samples 
will be separated into serum/plasma and red blood 
cells by low speed centrifugation (3000 rpm, 4°C for 
10 min). The following samples will be sent to a central 
pathology laboratory accredited by the National Associa-
tion of Testing Authorities Royal College of Pathologists 
Australasia: serum total cholesterol, high-density lipopro-
tein (HDL)-cholesterol and triglycerides will be analysed 
using an enzymatic colorimetric method (Roche Diag-
nostics, Mannheim). Low-density lipoprotein (LDL)-cho-
lesterol will be calculated using Friedewald’s formula. 
Serum creatinine, urea, albumin, calcium, phosphorus, 
sodium, potassium and phosphorus will be analysed using 
standardised techniques. Additional packed red blood 
cells, plasma and serum samples will be stored until anal-
ysed. Samples will be stored in a −70°C freezer prior to 
being transferred to Deakin University, where samples 
will be stored at –80°C until the study is complete. Eryth-
rocyte levels of omega-3 PUFAs will be extracted based on 
LePage and Roy method.82 The extracted fatty acids will 
be separated by gas chromatography, identified by the 
comparison with known fatty acid standards and quanti-
fied by comparison to the internal standard (21:0). Serum 
25(OH)D will be used to determine changes in vitamin D 
levels due to the supplement.
Apolipoprotein E (ApoE) status
ApoE is involved in lipid homeostasis, particularly in the 
determination of the levels of LDL and HDL cholesterol, 
which are directly and inversely correlated with risk for 
cardiovascular disease respectively.83 Carriers of the ApoE 
e4 allele have increased coronary risk,84 and e4 carriers 
also have a higher risk of developing late onset AD.85 
Although e4 carriers may experience a similar benefit 
from lifestyle based interventions, their rate of cognitive 
change may be greater than in non-carriers.86 ApoE status 
will be assessed at baseline (V1), DNA will be extracted 
from venous whole blood samples using commercially 
available kits.
Physical activity
The Community Healthy Activities Model Program 
for Seniors (CHAMPS) physical activity questionnaire 
will be used to calculate total leisure and recreational 
physical activity time. This measure has been designed 
for use in older adults and is reliable, valid and sensi-
tive to change.87Individuals will document their weekly 
frequency and duration of participation in a ‘typical 
week’ of the preceding 4 weeks. Outcomes will be hours 
per week, and estimated kilojoules per week, spent in 
moderate to high intensity activities.
To obtain an objective measure of physical activity, 
participants will be provided with an Actigraph monitor 
to wear for a period of up to 7 days on three occasions. 
The Actigraph is a small lightweight monitor that will be 
worn on the right hip to measure quantity and intensity 
of physical activity. Monitors will be removed for sleep. 
Participants will complete a log of their activity including 
sleep hours to aid in interpretation of this data. Physical 
activity information will be collected for the 7 days prior 
to V1, V2 and V3 assessments. Time spent in sedentary, 
light, moderate and vigorous activity will be calculated.
Diet
The Automated Self-Administered 24 hours (ASA24) 
Australia Dietary Assessment Tool (https:// epi. grants. 
cancer. gov/ asa24/) developed by the National Cancer 
Institute will be used as a 24-hour dietary recall. The 
ASA24 is completed online; however, it will be conducted 
over the phone with a researcher if participants do not 
have computer and internet access. The ASA24 allows 
respondents to report foods and drinks and amounts 
consumed by browsing a food category or searching from 
a list of food and drink terms derived from the 2007–2008 
National Health and Nutrition Examination Survey. The 
ASA-24 provides a breakdown of macronutrients and 
energy, vitamins, minerals, carotenoids, fats, cholesterol 
and fatty acids.
A validated online questionnaire will be used to assess 
dietary PUFA intake. The PUFA questionnaire is a simple 
non-invasive method that estimates the intakes of omega-3 
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and omega-6 PUFAs in a healthy adult population.88 The 
questionnaire includes main food sources of α-linolenic 
acid as well as omega-6 PUFA, linoleic acid (LA) and 
arachidonic acid (AA). The PUFA questionnaire consists 
of 38 questions relating to the usual dietary habits related 
to PUFA intake over 3 months. The questions pertain to 
foods, such as fish, meat and eggs for omega-3 PUFA, and 
vegetable oils and fats for omega-6 PUFA. The question-
naire covers fish oil supplement consumption and prod-
ucts with added omega-3 such as bread, eggs and milk.
statistical analysis
Data will be analysed using SPSS V.25 and STATA V.15 
applying standard statistical thresholds (p<0.05), 
corrected for multiple comparisons where appropriate. 
There will be no interim data analysis. All data will be 
checked for normality prior to analysis. Data will be 
analysed based on an intention-to-treat approach using 
linear mixed models with random effects. Changes in 
the primary outcomes (CogState global cognitive func-
tion and Trail making test of executive function), and all 
secondary outcomes will be expressed as the absolute or 
percentage difference for the change between the inter-
vention group and control group after 6 months or 12 
months, as appropriate. For the cognitive outcomes, the 
results will be analysed adjusted for age, gender and years 
of education (model 1) as well as baseline MoCA score 
and ApoE status (model 2). Per-protocol analysis will be 
used to determine the effectiveness of the intervention 
among participants who are considered to be compliant 
with the intervention. Participants who attended 67% 
(two-thirds) of exercise sessions and consumed 80% of 
the allocated supplement will be classified as adherent 
for the purpose of completer analysis. All data will be 
presented as mean±SD or 95% CIs.
Ethical approval, data management and dissemination plan
The current protocol is based on version 4, April 2017. 
The first participants were enrolled into the study on 
4 April 2017. In line with the ethical approval for this 
study, all data will be de-identified and stored in a locked 
filing cabinet or on a secure data drive at Deakin Univer-
sity. Only members of the research team will have access 
to the data. Only study investigators will have access to 
the final data set. Any changes to the trial protocol will 
be reported to Deakin University Human Research Ethics 
Committee and updated on the clinical trial registry. On 
completion of the trial, participants will receive a report 
outlining major study findings. They may also request 
pathology results. Study investigators will disseminate 
group results to the public in the form of journal arti-
cles, conference presentations, seminars and community 
presentations.
Patient and public involvement
Participants were not explicitly involved in the devel-
opment of the trial. Feedback will be sought from all 
participants at the end of the study to assess burden of 
intervention and to help develop future trials. Partic-
ipants will receive individual result summaries of key 
measures and a summary of the overall study findings.
dIsCussIon
Given that dementia is among one of the major causes 
of disability and death worldwide,89 interventions that 
prevent cognitive decline and delay the onset of dementia 
and related disorders are urgently needed. This study will 
be the first to evaluate whether a multifaceted intervention 
comprising of exercise combined with omega-3, vitamin 
D and protein supplementation can improve cognitive 
function in older adults at risk of cognitive decline and 
provide information about potential underlying mecha-
nisms. This study will evaluate the longer-term cognitive 
impact of the multifaceted intervention.
Age-related impairments to cognitive and physical func-
tion are multifactorial; therefore, multidomain interven-
tions that target multiple risk factors are needed to address 
a wider range of mechanisms involved in cognitive and 
functional decline. Promising results have been obtained 
from the large-scale, 2-year Finnish Geriatric Intervention 
Study to Prevent Cognitive Impairment and Disability 
(FINGER) trial, which examined the impact of a multi-
domain intervention on cognitive function in 1260 older 
adults aged 60–77 years, selected on the basis of elevated 
risk for dementia.90 The study intervention included four 
components including personalised and group dietary 
recommendations, an individually tailored exercise 
programme targeting progressive muscle strength and 
aerobic exercise, group and web-based cognitive training 
and management of metabolic and vascular risk factors 
compared with regular health advice. The results of this 
study demonstrated a significant benefit of the multi-
domain intervention to a composite cognitive score, 
a processing speed and executive function composite 
score, with improved or maintained cognitive function 
from 25% to 150% better than the control group. The 
only cognitive domain not to demonstrate an improve-
ment was memory. These findings are important as they 
suggest that making multiple lifestyle modifications can, 
in turn, modify cognition.
While the results of the MAPT did not show benefits of 
a combined multidomain and omega-3 fatty acid inter-
vention to the primary cognitive outcomes, some cogni-
tive improvements were seen for secondary outcomes and 
subgroup analyses. Currently, the SYNchronizing Exer-
cises, Remedies in Gait and Cognition (SYNERGIC) trial 
is underway to investigate whether a 20-week multimodal 
intervention combining aerobic and resistance training 
exercise, with or without cognitive training or vitamin D 
supplementation, can improve cognition and reduce falls 
in 200 adults with mild cognitive impairment.91 Similar to 
the current study, the SYNERGIC trial is focused on inter-
ventions that simultaneously target cognitive health and 
physical function. A common element of these studies 
is that they have incorporated cognitive training in the 
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multidomain interventions. Yet the addition of cognitive 
training to resistance training was less effective than exer-
cise alone for cognitive function in the SMART trial.13 
The premise of ‘overdosing’ by including too many life-
style intervention components has been suggested as a 
factor that may have contributed to these findings.92 In 
the current study, we have opted to limit the interven-
tion to exercise and dietary supplementation and not 
include cognitive training. The dietary component of 
the PONDER study is also restricted to a supplement, 
rather than individualised dietary counselling in order to 
simplify the lifestyle changes required to be undertaken 
by participants.
Similar to the FINGER study,90 a potential limitation of 
the current study is that it was not feasible to examine the 
isolated effects of the exercise programme and dietary 
supplement in separate study arms. However, the study 
aim is to evaluate the combined impact of the exercise 
programme and dietary supplement on cognitive func-
tion. The duration of the PONDER intervention is shorter 
than the larger FINGER and MAPT trials; however, the 
SMART trial demonstrated cognitive benefits after only 6 
months of resistance training13 indicating our study inter-
vention duration should be sufficient to modify cognitive 
function. Furthermore, our study includes an additional 
12-month follow-up to capture residual effects of the 
intervention. Finally, our study criteria does not exclude 
individuals with mild cognitive impairment, only those 
with dementia thus may include participants in the early 
stages of cognitive decline or preclinical dementia.
To summarise, this is the first RCT to investigate the 
combined effects of a multimodal exercise programme, 
omega-3 fatty acid, vitamin D and protein supplementa-
tion on cognitive function in older people with SMI. This 
study will contribute to a growing research field which 
assesses the effectiveness of multidomain, lifestyle-based, 
interventions for cognitive decline in the elderly.
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